VCYT
Veracyte, Inc. Health Care Services-Medical Laboratories Russell 3000
$50.01Close
$4.0BMarket cap
$30.01 – $60.4952-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 85 · stronger than 85% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · 50-day under the 150/200-day
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
up 4.3%
price change
1mo
up 8.6%
price change
12-month return
up 42%
market up 11% ·
its own up 30%
F-score
7 / 9
Strong
Altman Z″
15.66
Low risk
P/E
59.8×
price / earnings
PEG
0.36
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
up 1.6%
EBIT / enterprise value
Cheaper than
46%
of the market · around average
Revenue growth
up 16%
year on year
EPS growth
—
latest quarter
Sales growth
up 15%
latest quarter · -6 pts
ROE
up 5%
return on equity
Free cash margin
up 24%
$126.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-4.6×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- issued more shares
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
Repair signals
- Gross margin 66.9% → 70.1%
Trade setup
ATR%
4.9%
$2.44 a day · 2×ATR $45.12
RS
85 / 99
vs the universe
Trend
7 / 8
50-day under the 150/200-day
Relative volume
0.8×
vs 50-day average
Up/down volume
1.21
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 7 of 8
- 50-day average above the 150 and 200-day: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2.0% over the year, from 78m to 79m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 30, 2026
Last shock
Jul 31, 2026-23% in one session4.4× volumeon results+8% since
Financials
- Gross 70%
- Net 13%
- Free cash 24%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Gross margin | — | — | 59% | 64% | 67% | 70% |
| Operating income | -$35.4M | -$81.9M | -$41.1M | -$85.8M | $16.1M | $57.8M |
| Net income | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
| Net margin | -30% | -34% | -12% | -21% | 5% | 13% |
| Earnings per share | -$0.66 | -$1.11 | -$0.51 | -$1.02 | $0.31 | $0.82 |
| Free cash flow | -$12.5M | -$37.0M | -$1.0M | $34.3M | $63.8M | $126.6M |
| Free cash margin | -11% | -17% | -0% | 9% | 14% | 24% |
| Cash | $349.4M | $173.2M | $154.2M | $216.5M | $239.1M | $362.6M |
| Long-term debt | $810,000 | $0 | — | — | — | — |
| Shareholders' equity | $421.2M | $1.1B | $1.1B | $1.0B | $1.2B | $1.3B |
| Shares outstanding | 58.20m | 71.12m | 71.96m | 73.26m | 77.77m | 79.36m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 31, 2026 | Quarterly ↗ | Jun 30, 2026 | 31d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 14, 2026 | Material agreement · Acquisition or disposal · Regulation FD ↗ |
| Jul 30, 2026 | Results ↗ |
| Jun 11, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Mar 16, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 18, 2025 | Director or officer change · Shareholder vote ↗ |
| May 7, 2025 | Results ↗ |
| Feb 24, 2025 | Results ↗ |